SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 17, 2002; DOI 10.1182/blood-2002-01-0048. This Article Full Text (PDF) All Versions of this Article: 2002-01-0048v1 100/5/1525    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Couban, S. Articles by Lipton, J. H. Search for Related Content PubMed PubMed Citation Articles by Couban, S. Articles by Lipton, J. H. Social Bookmarking                   What's this? Submitted January 8, 2002 Accepted April 15, 2002 A Randomized Multicentre Comparison of Bone Marrow and Peripheral Blood in Recipients of Matched Sibling Allogeneic Transplants for Myeloid Malignancies Stephen Couban*, Stephen Couban, David R Simpson, David R. Simpson, Michael J Barnett, Michael J. Barnett, Christopher Bredeson, Christopher Bredeson, Lothar Hubesch, Lothar Hubesch, Kang Howson-Jan, Kang Howson-Jan, Tsiporah B Shore, Tsiporah B. Shore, Irwin R Walker, Irwin R. Walker, Peter Browett, Peter Browett, Hans A Messner, Hans A. Messner, Tony Panzarella, Tony Panzarella, Jeffrey H Lipton, and Jeffrey H. Lipton Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada North Shore Hospital, Takapuna, Auckland, New Zealand Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada; British Columbia Cancer Agency, Vancouver, British Columbia, Canada Statistical Center Statistical Center of the International Bone Marrow Transplant Registry, Health Policy Instituteof the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, USA Department of Medicine, Ottawa Hospital, Ottawa, Ontario, Canada; University of Ottawa, Ottawa, Ontario, Canada Department of Medicine, London Health Sciences Centre, London, Ontario, Canada; London Regional Cancer Centre, Department of Oncology, University of Western Ontario, London, Ontario, Canada New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA Department of Medicine, McMaster University, Hamilton, Ontario, Canada Division of Molecular Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada Department of Biostatistics, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada * Corresponding author; email: scouban{at}is.dal.ca. Background Cytokine-mobilized peripheral blood is increasingly used instead of bone marrow as the source of cells for allogeneic transplantation. While such cytokine-mobilized peripheral blood cells lead to faster hematologic recovery, their effects on graft-versus-host disease, relapse and survival are less certain. Methods Between January 1996 and February 2000, 228 patients with chronic myeloid leukemia, acute myeloid leukemia or myelodysplasia were randomized to receive either bone marrow or peripheral blood allografts from HLA-matched siblings. All patients received busulfan and cyclophosphamide as conditioning chemotherapy and cyclosporine and methotrexate as graft-versus-host disease prophylaxis. We compared the time to neutrophil and platelet recovery, acute and chronic graft-versus-host disease, relapse and overall survival between the two groups. Results The median time to neutrophil recovery was 19 days and 23 days and the time to platelet recovery was 16 days and 22 days in the peripheral blood and bone marrow groups (P<0.0001 for both comparisons). The cumulative incidence of grades II-IV acute graft-versus-host disease 100 days following transplant was 44% in both groups (hazard ratio, 0.99; 95% confidence interval, 0.66 to 1.49; P>0.9) and of extensive chronic graft-versus-host disease at 30 months post-transplant was 40% with peripheral blood and 30% with bone marrow (hazard ratio, 1.23; 95% confidence interval, 0.78 to 1.96; P=0.37). There was no statistically significant difference in the probability of relapse of the underlying disease between the two groups. The probability of survival at 30 months post-transplant was 68% and 60% in the peripheral blood and bone marrow groups respectively (hazard ratio, 0.62; 95% confidence interval, 0.39 to 0.97; P=0.04). Conclusions In patients with chronic myeloid leukemia, acute myeloid leukemia and myelodysplasia undergoing allogeneic transplantation from matched siblings, the use of peripheral blood instead of bone marrow leads to faster hematologic recovery, similar risk of graft-versus-host disease and improved survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Gallardo, R. de la Camara, J. B. Nieto, I. Espigado, A. Iriondo, A. Jimenez-Velasco, C. Vallejo, C. Martin, D. Caballero, S. Brunet, et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study Haematologica, September 1, 2009; 94(9): 1282 - 1288. [Abstract] [Full Text] [PDF] J. L. Irani, C. S. Cutler, E. E. Whang, T. E. Clancy, S. Russell, R. S. Swanson, S. W. Ashley, M. J. Zinner, and C. P. Raut Severe Acute Gastrointestinal Graft-vs-Host Disease: An Emerging Surgical Dilemma in Contemporary Cancer Care Arch Surg, November 1, 2008; 143(11): 1041 - 1045. [Abstract] [Full Text] [PDF] G. Gahrton, S. Iacobelli, G. Bandini, B. Bjorkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kroger, A. Schattenberg, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma Haematologica, November 1, 2007; 92(11): 1513 - 1518. [Abstract] [Full Text] [PDF] N. Schmitz, M. Eapen, M. M. Horowitz, M.-J. Zhang, J. P. Klein, J. D. Rizzo, F. R. Loberiza, A. Gratwohl, and R. E. Champlin Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation Blood, December 15, 2006; 108(13): 4288 - 4290. [Abstract] [Full Text] [PDF] K. M. Pastos, W. B. Slayton, L. M. Rimsza, L. Young, and M. C. Sola-Visner Differential effects of recombinant thrombopoietin and bone marrow stromal-conditioned media on neonatal versus adult megakaryocytes Blood, November 15, 2006; 108(10): 3360 - 3362. [Abstract] [Full Text] [PDF] C. Crawley, R. Szydlo, M. Lalancette, A. Bacigalupo, A. Lange, M. Brune, G. Juliusson, A. Nagler, A. Gratwohl, J. Passweg, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT Blood, November 1, 2005; 106(9): 2969 - 2976. [Abstract] [Full Text] [PDF] S. Z. Pavletic, I. F. Khouri, M. Haagenson, R. J. King, P. J. Bierman, M. R. Bishop, M. Carston, S. Giralt, A. Molina, E. A. Copelan, et al. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research J. Clin. Oncol., August 20, 2005; 23(24): 5788 - 5794. [Abstract] [Full Text] [PDF] Stem Cell Trialists' Collaborative Group Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials J. Clin. Oncol., August 1, 2005; 23(22): 5074 - 5087. [Abstract] [Full Text] [PDF] A. C. Lipkin, P. Lenssen, and B. J. Dickson Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art Nutr Clin Pract, August 1, 2005; 20(4): 423 - 439. [Abstract] [Full Text] [PDF] H. Wallen, T. A. Gooley, H. J. Deeg, J. M. Pagel, O. W. Press, F. R. Appelbaum, R. Storb, and A. K. Gopal Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older J. Clin. Oncol., May 20, 2005; 23(15): 3439 - 3446. [Abstract] [Full Text] [PDF] T. M. Cao, J. A. Shizuru, R. M. Wong, K. Sheehan, G. G. Laport, K. E. Stockerl-Goldstein, L. J. Johnston, M. J. Stuart, F. C. Grumet, R. S. Negrin, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose Blood, March 15, 2005; 105(6): 2300 - 2306. [Abstract] [Full Text] [PDF] D. A. Wall Allogeneic Peripheral Blood Versus Bone Marrow Transplantation: Children Are Small Adults and More J. Clin. Oncol., December 15, 2004; 22(24): 4865 - 4866. [Full Text] [PDF] M. Eapen, M. M. Horowitz, J. P. Klein, R. E. Champlin, F. R. Loberiza Jr, O. Ringden, and J. E. Wagner Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry J. Clin. Oncol., December 15, 2004; 22(24): 4872 - 4880. [Abstract] [Full Text] [PDF] R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors Blood, September 1, 2004; 104(5): 1550 - 1558. [Abstract] [Full Text] [PDF] C. S. Leger and T. J. Nevill Hematopoietic stem cell transplantation: a primer for the primary care physician Can. Med. Assoc. J., May 11, 2004; 170(10): 1569 - 1577. [Abstract] [Full Text] [PDF] D.C. Taussig, A.J. Davies, J.D. Cavenagh, H. Oakervee, D. Syndercombe-Court, S. Kelsey, J.A.L. Amess, A.Z.S. Rohatiner, T.A. Lister, and M.J. Barnett Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting J. Clin. Oncol., August 15, 2003; 21(16): 3060 - 3065. [Abstract] [Full Text] [PDF] M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine Stem Cell Mobilization Hematology, January 1, 2003; 2003(1): 419 - 437. [Abstract] [Full Text] [PDF] D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru Non-Myeloablative Transplantation Hematology, January 1, 2002; 2002(1): 392 - 421. [Abstract] [Full Text]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020